Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
2021 financial results in line with guidance
Group full year guidance (Q3 earnings October 2021)
In cc
Innovative
Medicines
Sandoz¹
Sales expected to grow mid single digit
Core Oplnc expected to grow high single digit
Sales expected to decline low to mid single digit
Core Oplnc expected to decline mid to high teens
Sales expected to grow low to mid single digit
Group
Core Oplnc expected to grow mid single digit, ahead of sales
1. FY sales growth for Sandoz includes +1% point impact from a reclassification of contract manufacturing from other revenue to sales.
40 Investor Relations | Q4 2021 Results
FY 2021 vs. PY
+6%
+10%
+
-2%
-14%
+4%
+6% ✓
NOVARTIS | Reimagining MedicineView entire presentation